Monopar Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Monopar Therapeutics Inc. (MNPR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $2.44 per share for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2023-05-11
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.44, a 70.13% decline year-over-year.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2022-03-31 was $8.17, a 52.64% decline year-over-year.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2021-03-31 was $17.25.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2020-03-31 was $0.00.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $6.13, a 5.55% decline from fiscal 2021.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2021 was $6.49, a 23.38% decline from fiscal 2020.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2020 was $8.47.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2018 was $6.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2023-03-31 | $2.44 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $6.13 10-K · filed 2023-03-23 | |||
| 2022-09-30 | $6.13 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $5.54 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $8.17 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $6.49 10-K · filed 2023-03-23 | |||
| 2021-09-30 | $9.33 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | $9.33 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | $17.25 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | $8.47 10-K · filed 2022-03-24 | |||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $0.00 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $0.00 10-Q · filed 2020-11-12 | |||
| 2019-09-30 | $0.00 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-10 | |||
| 2018-12-31 | $6.00 10-K · filed 2020-03-27 | |||
| 2018-09-30 | $6.00 10-Q · filed 2018-11-09 | |||
| 2018-06-30 | $6.00 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-11 | |||
| 2017-12-31 | $0.00 10-K · filed 2019-02-26 | |||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | $0.00 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |